最新消息 - 昱厚生技股份有限公司

November 19, 2019

First Subject Screened in Cohort 2 (Mid-Dose Group) of Phase Ib/IIa Trial for AD17002-AI House Dust Mite-Induced Allergic Rhinitis Treatment; Target Enrollment is 16 Subjects for this Cohort.

Updates

November 18, 2019

Phase II Clinical Trial Results of Advagene's Intranasal Influenza Vaccine Published in the Prestigious International Journal Vaccine.

Updates

November 14, 2019

Safety Review Team Meeting Held for Cohort 1 (Low-Dose Group) of AD17002-AI House Dust Mite-Induced Allergic Rhinitis Trial; Expert Committee Approves Enrollment for Next Phase Mid-Dose Group.

Updates

October 1, 2019

Phase Ib/IIa Trial of AD17002-AI House Dust Mite-Induced Allergic Rhinitis Treatment Completes Testing and 8-Week Hospital Follow-up for All Subjects in Cohort 1 (Low-Dose Group).

Updates

March 30, 2019

【中時/工商時報】昱厚噴鼻疫苗研究成果獲國際疫苗期刊登載

Press

Company

Introduction

Team & Board of Directors

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Company

R&D Pipeline

Latest News

First Subject Screened in Cohort 2 (Mid-Dose Group) of Phase Ib/IIa Trial for AD17002-AI House Dust Mite-Induced Allergic Rhinitis Treatment; Target Enrollment is 16 Subjects for this Cohort.

Phase II Clinical Trial Results of Advagene's Intranasal Influenza Vaccine Published in the Prestigious International Journal Vaccine.

Safety Review Team Meeting Held for Cohort 1 (Low-Dose Group) of AD17002-AI House Dust Mite-Induced Allergic Rhinitis Trial; Expert Committee Approves Enrollment for Next Phase Mid-Dose Group.

Phase Ib/IIa Trial of AD17002-AI House Dust Mite-Induced Allergic Rhinitis Treatment Completes Testing and 8-Week Hospital Follow-up for All Subjects in Cohort 1 (Low-Dose Group).

【中時/工商時報】昱厚噴鼻疫苗研究成果獲國際疫苗期刊登載

Company

Introduction

Team & Board of Directors

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Company

R&D Pipeline

Latest News

First Subject Screened in Cohort 2 (Mid-Dose Group) of Phase Ib/IIa Trial for AD17002-AI House Dust Mite-Induced Allergic Rhinitis Treatment; Target Enrollment is 16 Subjects for this Cohort.

Phase II Clinical Trial Results of Advagene's Intranasal Influenza Vaccine Published in the Prestigious International Journal Vaccine.

Safety Review Team Meeting Held for Cohort 1 (Low-Dose Group) of AD17002-AI House Dust Mite-Induced Allergic Rhinitis Trial; Expert Committee Approves Enrollment for Next Phase Mid-Dose Group.

Phase Ib/IIa Trial of AD17002-AI House Dust Mite-Induced Allergic Rhinitis Treatment Completes Testing and 8-Week Hospital Follow-up for All Subjects in Cohort 1 (Low-Dose Group).

【中時/工商時報】昱厚噴鼻疫苗研究成果 獲國際疫苗期刊登載

【中時/工商時報】昱厚噴鼻疫苗研究成果獲國際疫苗期刊登載